International Journal of Cancer Management

Published by: Kowsar
Crossmark

A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran

Roham Salek 1 , Fatemeh Varshoee Tabrizi 2 , Kamran Ghaffarzadegan 3 , Golnaz Sabouri 4 and Azar Fanipakdel 1 , *
Authors Information
1 Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Reza Radiation Oncology Center, Mashhad, Iran
3 Pathology Department, Razavi Hospital, Mashhad, Iran
4 Clinical Governance Department, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Iranian Journal of Cancer Prevention: January 2017, 10 (1); e4371
  • Published Online: January 18, 2017
  • Article Type: Research Article
  • Received: November 14, 2015
  • Revised: February 1, 2016
  • Accepted: January 3, 2017
  • DOI: 10.17795/ijcp-4371

How to Cite: Salek R, Varshoee Tabrizi F, Ghaffarzadegan K, Sabouri G, Fanipakdel A. A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran, Int J Cancer Manag. 2017 ; 10(1):e4371. doi: 10.17795/ijcp-4371.

Abstract
Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. WHO. . Iranian annual of national cancer registration report, 2005-2006.
  • 2. Ferlay J, Shin HR, Bray F. Cancer incidence and mortality worldwide, international agency for research on cancer. 2010;
  • 3. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J. 2009; 15(6) : 1426 -31 [PubMed]
  • 4. Sharifian A, Pourhoseingholi MA, Emadedin M, Rostami Nejad M, Ashtari S, Hajizadeh N, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015; 16(12) : 5049 -52 [PubMed]
  • 5. Gianni B, Gabriel NH, Pinuccia V. Textbook of breast cancer aclinical guide to therapy. 2006; : 86
  • 6. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27(27) : 4515 -21 [DOI][PubMed]
  • 7. Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med. 2009; 133(6) : 860 -8 [DOI][PubMed]
  • 8. Katrina RB, Monica B, Rosemary DC, Carol AP, Vincent C. Descriptive analysis of estrogen receptor (er)- negative, progesterone receptor (pr)- negative, and her2- negative invasive breast cancer, the so- called triple- negative phenotype. Cancer. 2007;
  • 9. Francesca R, Sandra B, Amalia F, Angelo M, Camilla C, Romeo B, et al. Triple-negative breast cancer:current state of the art. Tumori. 2010; 96 : 875 -88
  • 10. Nielsen TO. Immunohistochemical and clinical characterization of basal- like subtype of invasive breast carcinoma. Clinical Cancer Res. 2004; : 5367 -74
  • 11. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15) : 2568 -81 [DOI][PubMed]
  • 12. Rubovszky G, Udvarhelyi N, Horvath Z, Lang I, Kasler M. [Triple-negative breast carcinoma--rewiev of current literature]. Magy Onkol. 2010; 54(4) : 325 -35 [DOI][PubMed]
  • 13. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer. 2008; 15(4) : 303 -8 [DOI][PubMed]
  • 14. Mise M, Higashide S, Hashimoto K, Kawada K, Hanaki K, Kanda Y, et al. [Clinicopathological features of young patients with triple negative breast cancer]. Gan To Kagaku Ryoho. 2009; 36(10) : 1677 -81 [PubMed]
  • 15. Gerson R, Alban F, Villalobos A, Serrano A. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype]. Gac Med Mex. 2008; 144(1) : 27 -34 [PubMed]
  • 16. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113(2) : 357 -70 [DOI][PubMed]
  • 17. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, et al. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat. 2010; 123(1) : 177 -87 [DOI][PubMed]
  • 18. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007; 14(6) : 419 -30 [DOI][PubMed]
  • 19. Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N. Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr. 2010; 20(1) : 17 -34 [PubMed]
  • 20. Lee JH, Kim SH, Suh YJ, Shim BY, Kim HK. Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. Cancer Res Treat. 2010; 42(1) : 30 -6 [DOI][PubMed]
  • 21. Koo JS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J. 2011; 52(1) : 89 -97 [DOI][PubMed]
  • 22. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008; 52(1) : 108 -18 [DOI][PubMed]
  • 23. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19(2) : 264 -71 [DOI][PubMed]
  • 24. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007; 7 : 134 [DOI][PubMed]
  • 25. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14(5) : 1368 -76 [DOI][PubMed]
  • 26. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447(4) : 688 -94 [DOI][PubMed]
  • 27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9) : 1217 -26 [DOI][PubMed]
  • 28. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007; 67(2) : 501 -10 [DOI][PubMed]
  • 29. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11(14) : 5175 -80 [DOI][PubMed]
  • 30. Koronakis N, Karanikas G, Lagoudianakis EE, Grosomanidis D, Pappas A, Chrysikos J, et al. Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients. Eur J Gynaecol Oncol. 2010; 31(3) : 304 -7 [PubMed]
  • 31. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007; 60(9) : 1006 -12 [DOI][PubMed]
  • 32. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20) : 1938 -48 [DOI][PubMed]
  • 33. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008; 14(5) : 456 -63 [DOI][PubMed]
  • 34. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009; 153(1) : 13 -7 [PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments